To discuss India's growing role in the drug discovery, development and bioprocessing markets, IBC Life Sciences, a worldwide leader in scientific, technological and business conferences and courses for the life science industry, would organise fifth Annual Drug Discovery and Development of Innovative Therapeutics India conference and third BioProcess International Asia Pacific conference in Mumbai from October 20 to 22, 2008.
To be held at the Grand Hyatt Hotel, this two-day conference would bringing together chief executive officers of leading companies, therapeutic area experts, top scientists, research and development heads, investors, regulatory experts and business executives from India, USA and Europe to share new technologies, novel targets, scientific strategies, exciting molecules, portfolio-building approaches and partnering strategies in metabolic disease, cancer, central nervous system and inflammation.
"It is an opportunity to learn about multiple business models and partnering strategies to help one identify potential collaborators, assets and investment opportunities. Drug discovery and development is a global endeavour conducted across several geographies, in multiple time zones and very often with multiple partners and collaborators," said the organisers.
"IBC's third BioProcess International Asia Pacific conference, to be held in India for the first time, is strategically set in Mumbai to allow companies to come together to explore growth and partnership opportunities, ramp up their learning curve on processing techniques as well as increase their production quickly and cost-effectively," they noted.
Eminent corporate leaders representing associations like ABLE and corporate houses such as Ranbaxy, Zydus Cadila, Glenmark Pharmaceuticals, Reliance Biopharmaceutical Pvt Ltd, Shantha Biotech, Biological E Limited, ABLE, Serum Institute of India Limited, and Biogen Ide are expected to engage the conference sessions.